Hepatologists, both researchers and front-line clinicians, now have a comprehensive guide to the treatment of patients with the HCV virus. This book focuses mainly on the efficacy and clinical use of antiviral therapies, including the use of antivirals post liver transplantation and in the presence of the HIV virus. It also explores the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs. A 'late-breaking information' chapter contains the most recent trial results on the latest antiviral drugs.
Professor Geoff McCaughan is Director of the AW Morrow Liver Centre and Physician in Charge at the Australian National Liver Transplant Unit. John McHutchison is a professor of medicine at Duke University Medical Center, and since 2002, Director of the DCRI s Gastroenterology and Hepatology Research division.
Contributors vii Preface xi Section I Foundations for Understanding Antiviral Therapies in HCV 1 HCV Replication 3 Michael R. Beard 2 Hepatitis C Virus Genotypes 12 Scott A. Read and Mark W. Douglas 3 Immune Responses to HCV: Implications for Therapy 17 David G. Bowen 4 Mechanisms of Action of Antiviral Drugs: The Interferons 25 Edmund Tse and Michael R. Beard 5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs 36 Fred Poordad and Grace M. Chee 6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors 43 Lotte Coelmont Leen Delang Mathy Froeyen Piet Herdewijn and Johan Neyts 7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors 53 Laurent Chatel-Chaix Martin Baril and Daniel Lamarre 8 Measuring Antiviral Responses 60 Jean-Michel Pawlotsky and Stephane Chevaliez Section II Efficacy and Clinical Use of Antiviral Therapies 9 Genotype 1: Standard Treatment 67 Rebekah G. Gross and Ira M. Jacobson 10 Individually Tailored Treatment Strategies in Treatment-naive Chronic Hepatitis C Genotype 1 Patients 74 Johannes Wiegand and Thomas Berg 11 Genotype 1 Relapsers and Non-responders 84 Salvatore Petta and Antonio Craxi 12 Standard Therapy for Genotypes 2/3 90 Kenneth Yan and Amany Zekry 13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3 97 Alessandra Mangia Leonardo Mottola and Angelo Andriulli 14 Genotypes 2 and 3 Relapse and Non-response 104 Stella Mart'inez Jose Maria Sanchez-Tapias and Xavier Forns 15 Hepatitis C Genotype 4 Therapy: Progress and Challenges 113 Sanaa M. Kamal 16 Antivirals in Acute Hepatitis C 127 Heiner Wedemeyer 17 Antivirals in Cirrhosis and Portal Hypertension 132 Diarmuid S. Manning and Nezam H. Afdhal 18 Treatment of Recurrent Hepatitis C Following Liver Transplantation 140 Ed Gane 19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations 150 Benjamin Terrier and Patrice Cacoub 20 Cytopenias: How they Limit Therapy and Potential Correction 160 Mitchell L. Shiffman 21 The Problem of Insulin Resistance and its Effect on Therapy 169 Venessa Pattullo and Jacob George 22 HIV and Hepatitis C Co-infection 177 Gail V. Matthews and Gregory J. Dore 23 HCV and Racial Differences 185 Andrew J. Muir 24 HCV and the Pediatric Population 190 Kathleen B. Schwarz 25 New Horizons: IL28 Direct-acting Antiviral Therapy for HCV 196 Alexander J. Thompson John G. McHutchison and Geoffrey W. McCaughan Index 215